• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    434.22 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 434.22
    Bid (Size) 434.87 (1)
    Ask (Size) 435.58 (1)
    Prev. Close 434.22
    Today's Range 434.22 - 434.22
    52wk Range 327.73 - 550.76
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
    From argenx SE
    Via GlobeNewswire
    Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
    The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    +13.97%
    +13.97%
    1 Month
    +14.90%
    +14.90%
    3 Month
    +9.28%
    +9.28%
    6 Month
    +13.97%
    +13.97%
    1 Year
    +13.80%
    +13.80%

    More News

    Read More
    Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
    Via Investor's Business Daily
    Exposures Product Safety
    Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Breaking Down argenx: 12 Analysts Share Their Views
    Via Benzinga
    The Analyst Verdict: argenx In The Eyes Of 12 Experts
    Via Benzinga
    argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    From argenx SE
    Via GlobeNewswire
    After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
    Via Investor's Business Daily
    Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
    Via Benzinga
    Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
    Via Investor's Business Daily
    Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    argenx Reports First Quarter 2024 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire
    argenx announces results of Annual General Meeting of Shareholders
    From argenx SE
    Via GlobeNewswire
    argenx to Present at BofA Securities 2024 Health Care Conference
    From argenx SE
    Via GlobeNewswire
    argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
    From argenx SE
    Via GlobeNewswire
    argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
    From argenx SE
    Via GlobeNewswire
    Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
    Via Benzinga
    argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
    From argenx SE
    Via GlobeNewswire
    argenx Announces Annual General Meeting of Shareholders on May 7, 2024
    From argenx SE
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.